KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer https://t.co/MduSlA1kIo

🫁 Tumour–microenvironment crosstalk in #NSCLC drives resistance, metastasis, and outcomes. Understanding spatial niches, inflammation, and immune evasion can reshape treatment strategies. 📖 @NatRevClinOncol 👉 https://t.co/tOaPR0iiMY #CánCare #immunotherapy #biomarkers

This #BriefReview focuses on interferon (IFN) production in the thymus and its effects on thymic antigen presenting cells and developing thymocytes examining the importance of T-cell tolerance to IFN and interferon-stimulated proteins. Read more: https://t.co/JO4mpmXqJ7.

New #JITC review: Tumor organoids in immunotherapy: from disease modeling to translational research https://t.co/BWS7PDGggJ

Today, we honor the enduring legacy of Dr. Michael E. DeBakey, a visionary surgeon, educator and medical pioneer whose groundbreaking work transformed cardiovascular surgery. Dr. DeBakey died on this day in 2008 at the age of 99, leaving behind a legacy that continues to shape

Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma https://t.co/PKLLV7JZcS. @CCR_AACR, @BCM_SOIL, @BCM_Surgery, @bcmhouston. #mesothelioma #Immunotherapy

🗨️ “Vaccines have done more to improve public health than any other medical intervention.” A Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve

This week we launched our “How To Workshop Series” with a session on understanding the grant review process, crafting specific aims, and developing a competitive research plan. Featuring: Livia Eberlin, Ravi Ghanta, Thomas Milner, Tamer Mohamed, Hyun-Sung Lee, R. Taylor Ripley,

A #TopRead article from Dr. Jesse Bruijnesteijn found that a diverse repertoire of killer cell immunoglobulin-like receptors (KIRs) contributes to the protection of individuals and populations against pathogen evasion and subversion. Read it in The JI: https://t.co/uO3IkyZQYq

The innate power of NK cells in cancer therapy @MalmbergLab @NatureMedicine on @lab_rezvani trial https://t.co/1infXSaiEd

TNM classification 9ᵗʰ edition T stage https://t.co/yA7h7sgLYH

For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review https://t.co/oYPCyIOa8c https://t.co/P0NxIsUzKc

Check out the new paper by HS Lee, @BMBurtMD, @ShandaBlackmon et al about a prognosticator in pleural #mesothelioma. @BCM_Surgery @bcmhouston

New evidence today @NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers https://t.co/J8zAskV32l https://t.co/3uvAc03p8K

Online now: Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity

"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" https://t.co/NfkdnoE8uD @pfizer Lars Anders @Cancer_Cell

Breaking the mold: Unconventional T cells in cancer therapy https://t.co/D0MEyEvm91

EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models https://t.co/xrAqZKvGgp

Most viewed in the last 7 days from @JAMAOnc: Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. https://t.co/n91YeokYnL

Read the In the Spotlight commentary "MHC-Hammer decodes HLA disruption in tumors" https://t.co/7I7CrTS2yX By Timothy Sears and Hannah Carter discussing a recent @NatureGenet paper by @NickyMcGranahan @CharlesSwanton et al.